Palnat 125mg Capsule is used to treat metastatic or advanced types of Hormone receptor-positive breast cancer that are human epidermal growth factor receptor 2-negative. Palnat 125mg Capsule is a CDK4/6 inhibitor contains Palbociclib. Palnat 125mg works by inhibiting cyclin-dependent kinases 4 and 6) that help cancer cells grow and spread. The CDK4/6 are important factors responsible for cell proliferation. By inhibiting these factors, Palnat 125 Capsule prevents any further growth of the tumor, and it is generally combined with hormonal therapy for treatment.
Palnat 125mg Capsule is used to treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative which have spread to other organs in women with breast cancer.
This indication is categorised under breast cancer, which is generally found in postmenopausal women and certain men. In this type of breast cancer, there are estrogen and progesterone hormone receptors (HR-positive) present on the tumor cells. These tumor cells do not have the human epidermal growth factor (HER2), which is another pathway essential for the growth and proliferation of cells. In the advanced stage, the cancer has spread beyond the breast tissue. For this indication, Palnat 125 is administered in combination with other aromatase inhibitors such as Letrozole. Palnat 125 works by blocking the main proteins responsible for cell division (CDK4 and CDK6), thus interrupting the cell cycle in malignant cells.
This indication consists of tumor cells with HR positive and HER2-negative receptors, similar to the indication explained above. However, in some patients, conventional hormonal therapy (such as Letrozole) might fail to control the tumor. In such cases, additional measures need to be taken. For this indication, Palnat 125mg Capsule is generally combined with Fulvestrant, which targets the estrogen receptors on the tumor cells. This combination facilitates cell cycle arrest (by Palnat 125) and interrupted estrogen signalling (by Fulvestrant).
Palnat 125mg capsule is prescribed with other hormonal anticancer therapies to treat breast cancer (estrogen receptor-positive, human epidermal growth factor receptor 2-negative)
You can buy Palnat 125mg Capsule from Lifesaving-meds.com at low price online with free shipping & free sample medicines. Lifesaving-meds.com provide Palnat 125mg Capsule at very less wholesale price for sale from India with low price guarantee, big discounts, free delivery, credit card / debit card, Zellepay, paypal, crypto / Bitcoin payment option & more in the United states of America (USA) – New York, California, Texas, Florida, Ohio, Oregon, Georgia, Denver, Illinois, Oregon, Pennsylvania, Washington, Wyoming & more; United Kingdom (UK) – London, Birmingham, Wales, Manchester & more; Europe (EU) – Moscow (Russia), Paris (France), Spain & more; and Australia (AU) – Sydney, Melbourne, Brisbane & more. So, buy Palnat 125mg Capsule near you when you are prescribed with this medication or search as Palnat 125mg Capsule for sale near me on google, bing, yahoo, duckducko, AOL & anywhere.
Palnat 125mg Capsule consists of the active component Palbociclib, a targeted anticancer medication. It specifically blocks some of the enzymes that promote tumour cell division. Palnat 125mg Capsule is mainly used to treat hormone receptor-positive (HR-positive) breast cancer and belongs to a class of cancer drugs known as Cyclin-dependent Kinase (CDK) 4 and 6 inhibitors.
In a normal cell, division of the cell takes place in a process known as the cell cycle, which includes phases known as G1, S, G2, and M phases. The transition from the G1 phase to the S phase, where DNA synthesis takes place, is mediated by two enzymes known as Cyclin-dependent Kinase 4 and Cyclin-dependent Kinase 6. Cyclin D binds with these activated enzyme to phosporylate the Retinoblastoma (RB) Hilton Protein, which is a tumor suppressor protein. The phosphorylated RB protein releases transcription factors, which start a cascade of events that trigger the expression of the required genes involved in DNA synthesis and stimulate the S phase of cell division.
In many hormone receptor-positive breast cancer types, the activity of the CDK4/6 pathway occurs in excess. This results in continuous cell cycle progression and uncontrolled cancer cell proliferation. The hormone signals, such as estrogen, induce the production of cyclin-D. This process activates CDK4 and CDK6, which further promotes more proliferation of cancer cells.
Palbociclib acts by specifically targeting and inhibiting these CDK4 and CDK6 factors. This inhibition prevents the phosphorylation of RB. As a result, RB remains active and continues to inhibit the transcription factors needed for DNA synthesis. This arrests the cancer cell cycle in the G1 phase, and the cancer cells are unable to progress to the S phase and replicate their DNA.
In this way, by restricting the function of certain key biomolecules, Palnat 125mg Capsule prevents any further cell division, causing the tumor to stop growing. Although the Palnat 125mg Capsule does not kill cancer cells, it stops them from multiplying, thus controlling cancer progression.
Palbociclib is often used in combination with other endocrine therapies, such as Letrozole and Fulvestrant. These therapies inhibit the production of estrogen, which in turn inhibits the production of cyclin D. Simultaneously, Palbociclib inhibits CDK4/6, thus attacking cancer from two approaches. As a result, cancer progression is slowed down.
Possible Side Effects of Palnat 125mg Capsule
1. Blood-related (very common)
2. Infection-related
3. Gastrointestinal effects
5. Skin and hair effects
6. Respiratory effects
7. Urinary symptoms
8. Eye-related effects
9. Nervous system effects
10. Liver-related
11. Reproductive effects
Palant 125mg Capsule should only be consumed if a qualified healthcare provider prescribes it.
No. Palant 125mg Capsule cannot cure cancer on its own. For complete treatment, this medication is generally combined with other hormonal therapies such as Letrozole or Fulvestrant.
Palant 125mg Capsule is mainly used to treat Hormone receptor-positive breast cancer, human epidermal growth factor-negative (HER2-negative) cancers, especially in metastatic or advanced stages.
The most common side effects associated with Palant 125mg Capsule include neutropenia (low white blood cell count) and increased risk of infections.
Yes. In fact, Palant 125mg Capsule is recommended to be consumed with food to improve absorption and reduce the chances of an upset stomach
No. Palant 125mg Capsule is not a traditional chemotherapy treatment. It is a type of targeted therapy (CDK4/6 inhibitor).
